Fig. 2.
Effects of PPI2, endothall, or cyclosporine A on 17β-estradiol mediated neuroprotection in HT-22 cells and C6-glioma. HT-22 (A–C) and C6-glioma (D–F) cells were seeded into 96-well plates at a density of 3500 cells/well. (A and D) Cells were treated simultaneously with with 200 nM PPI2, 10 mM glutamate, and/or 10 μM 17β-estradiol. (B and E) Cells were treated simultaneously with 9 μM endothall, 10 mM glutamate, and/or 10 μ 17β-estradiol. (C and F) Cells were treated simultaneously with 500 nM CsA, 10 mM glutamate, and/or 10 μ 17β-estradiol. Cell viability was determined by calcein AM assay (Molecular Probes, Eugene, OR) after 24 h exposure to the various compounds. All data were normalized to % survival of non-treated control. Depicted are mean ± SEM for 10 independent experiments with two replicates per experiment. *P < 0.05 vs. vehicle control; †P < 0.05 vs. glutamate treated group.